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SUMMARY Endoscopic gastric biopsy specimens taken in 1976 from 174 patients were reviewed. Biopsy specimens from 44 patients showed intestinal metaplasia, and subtyping by mucin histochemistry showed that 16 68 patients with gastric adenocarcinoma diagnosed in 1985 were reviewed for evidence of intestinal metaplasia in a previous gastric biopsy. Only two patients had previously been biopsied; one of these biopsy specimens showed type II intestinal metaplasia and the other showed no intestinal metaplasia.
These findings suggest that subtyping of intestinal metaplasia in endoscopic gastric biopsy specimens is of only limited value in identifying patients at risk of gastric adenocarcinoma who require long term follow up.
Although the association between intestinal metaplasia and gastric carcinoma has long been recognised,' the prevalence of intestinal metaplasia in benign gastric conditions has precluded its use as an aid to the diagnosis of gastric carcinoma. Recent work has focused on the subtyping of intestinal metaplasia using mucin histochemistry. One We believe that our data showing only a low proportion of patients with type III intestinal metaplasia developing gastric carcinoma are not necessarily incompatible with the findings of previous studies showing type III intestinal metaplasia to be significantly more common in gastric carcinoma than in benign gastric disease. The probable reason is apparent if we look at the likely outcome for patients presenting for endoscopy and biopsy who do not already have gastric carcinoma. Of these patients, only a small number will be destined to develop gastric carcinoma while a much larger number will never develop gastric carcinoma. Although a high proportion of the former very small group may show type III intestinal metaplasia, this will yield only a small number of patients with type III intestinal metaplasia. If even a small proportion of the others (who will never develop gastric carcinoma) show type III intestinal metaplasia this will produce a sufficiently large number of such patients to swamp the small numbers of patients from the former group. The specificity of the screening system will therefore be reduced.
In a study of this type the possibility must be considered that we Ranesar, Sanders, Hopwood health screening method arises if the at risk population is not being screened. One might imagine that patients undergoing gastroscopy for benign conditions might form an at risk group as it has been shown that patients with gastritis have an increased incidence of gastric carcinoma. 16 We found, however, that only t.wo of 68 patients presenting with gastric carcinoma in 1985 had ever had upper gastrointestinal endoscopy and biopsy despite a high rate of endoscopy in this area and its availability for more than a decade. Thus even if type III intestinal metaplasia detection was a good predictor of gastric carcinoma risk, its impact on the incidence and morbidity in the community would be minimal unless there was a radical increase in endoscopy rate. Even this is doubtful as Holdstock etall' have shown that a 10-fold increase in endoscopy uptake in one area did not increase the detection rate of early gastric cancer.
It can be argued that the question of predictive value of type III intestinal metaplasia for subsequent gastric carcinoma can be more precisely answered by prospective studies. We believe, however, that guidelines on management of these patients are urgently required and that a retrospective approach is justified. Many pathologists and clinicians will be considering routine mucin histochemistry on gastric biopsy specimens with regular endoscopic follow up of patients with type III intestinal metaplasia. Such a policy would require reallocation of scarce laboratory and clinical resources. On the basis of the available information we conclude that such an approach is not justified and that detection of type III intestinal metaplasia is of limited value as an indicator of risk of gastric carcinoma.
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